Loading
Immunotherapy and Immune Responses / Vaccines and Immunoinformatics Approaches · Journal article
Therapeutic Advances in Vaccines and Immunotherapy · September 1, 2026
A consensus or society position rather than new primary data.
This is a narrative review of therapeutic melanoma vaccine platforms and emerging combination strategies with ICIs, summarizing the landscape of vaccine engineering, neoantigen approaches, and clinical trial activity. The manuscript identifies current vaccine modalities (peptide, dendritic cell, mRNA, DNA, viral vector) and highlights the integration of AI/ML for epitope prediction, while acknowledging persistent barriers to clinical adoption including tumor heterogeneity and manufacturing complexity.
Narrative review. Patients with melanoma and those who may benefit from personalized neoantigen vaccines combined with checkpoint inhibitors.
Melanoma vaccines target TAAs, TSAs, and personalized neoantigens to stimulate tumor-specific immune responses Personalized neoantigen vaccines and AI/ML-enhanced epitope prediction are accelerating vaccine development Combination strategies with anti-PD-1 and anti-CTLA-4 ICIs enhance vaccine efficacy by overcoming immune suppression
Safety and immunogenicity described as 'encouraging' but specific incidence or response magnitude figures not given Many vaccine studies have reported encouraging safety and immunogenicity findings, but widespread clinical implementation remains limited
Clinicians should recognize that melanoma vaccine development is advancing through multiple platforms and increasingly incorporates personalized neoantigen approaches and combination ICI strategies; however, the review indicates these remain primarily investigational with challenges limiting current clinical implementation.
A narrative review synthesizing current melanoma vaccine strategies, technologies, and clinical trial landscape without presenting original experimental data or meta-analysis of outcomes.
As stated by the source record.
Clinicians should recognize that melanoma vaccine development is advancing through multiple platforms and increasingly incorporates personalized neoantigen approaches and combination ICI strategies; however, the review indicates these remain primarily investigational with challenges limiting current clinical implementation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Melanoma has emerged as a major focus of cancer immunotherapy research because of its highly immunogenic nature and responsiveness to immune-based treatments. Therapeutic melanoma vaccines are designed to stimulate tumor-specific immune responses through the delivery of Tumor-Associated Antigens (TAAs), Tumor-Specific Antigens (TSAs), and personalized neoantigens. This narrative review provides an overview of current melanoma vaccine strategies, including peptide-based vaccines, dendritic cell vaccines, nucleic acid-based platforms such as mRNA, DNA, and viral vector vaccines. Recent advances in vaccine engineering and tumor genomics have accelerated the development of personalized neoantigen vaccines capable of targeting mutations unique to individual tumors. In parallel, Artificial Intelligence (AI) and Machine Learning (ML) are increasingly being incorporated into neoantigen identification pipelines to improve epitope prediction and optimize vaccine design. Combination strategies involving Immune Checkpoint Inhibitors (ICIs), particularly anti-PD-1 and anti-CTLA-4 therapies, have further enhanced interest in melanoma vaccines by helping overcome tumor-induced immune suppression and augment T-cell activation. In addition to reviewing vaccine mechanisms and emerging technologies, this manuscript examines the evolving clinical trial landscape through analysis of melanoma vaccine studies registered on ClinicalTrials.gov. Although many studies have reported encouraging safety and immunogenicity findings, challenges related to tumor heterogeneity, immune evasion, biomarker selection, and manufacturing complexity continue to limit widespread clinical implementation. Ongoing advances in computational immunology, biomaterial engineering, and precision oncology are expected to further refine melanoma vaccine development and improve therapeutic efficacy. Collectively, these innovations may help establish melanoma vaccines as an increasingly important component of future personalized cancer immunotherapy strategies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.